Skip to content
AwardedUnited KingdomServices£140,671

Blood Group Genotyping for Sickle Cell and Thalassaemi

Published
Published 3 September 2025
Deadline
Closed 5 May 2025

Overview

The main output of this programme is for blood group genotyping to become embedded into routine practice. Primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping.

Key details

Country
United Kingdom
Status
Awarded
Category
Services
Estimated value
£140,671
SME suitable
Yes
Published
3 September 2025
Deadline
Closed
Classification (CPV)
Blood analysis services

Award outcome

Awarded value
£140,671
Award date
12 May 2025
Contract period
11 May 2025 → 31 March 2026
Winner
  • NHS BLOOD AND TRANSPLANT (NHSBT)

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    3 September 2025

Contracting authority

  • NHS England, Leeds

    Buyer

    Leeds, United Kingdom

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Blood Group Genotyping for Sickle Cell and Thalassaemi — won by NHS BLOOD AND TRANSPLANT (NHSBT) — Skim